JP2025509106A - タンパク質発現を増強するための、配列内リボソーム進入部位（ＩＲＥＳ）、プラスミドベクター及び環状ｍＲＮＡ - Google Patents

タンパク質発現を増強するための、配列内リボソーム進入部位（ＩＲＥＳ）、プラスミドベクター及び環状ｍＲＮＡ Download PDF

Info

Publication number
JP2025509106A
JP2025509106A JP2024549763A JP2024549763A JP2025509106A JP 2025509106 A JP2025509106 A JP 2025509106A JP 2024549763 A JP2024549763 A JP 2024549763A JP 2024549763 A JP2024549763 A JP 2024549763A JP 2025509106 A JP2025509106 A JP 2025509106A
Authority
JP
Japan
Prior art keywords
ires
orf
plasmid vector
encoding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509106A5 (https=
Inventor
パトムポン ウォントラコーンゲイト
スラデジ ホンゲン
Original Assignee
バイオ アドヴェンチャー カンパニー リミテッド
マヒドン ユニヴァーシティ
オフィス オブ ナショナル ハイヤー エデュケイション サイエンス リサーチ アンド イノヴェイション ポリシー カウンシル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ アドヴェンチャー カンパニー リミテッド, マヒドン ユニヴァーシティ, オフィス オブ ナショナル ハイヤー エデュケイション サイエンス リサーチ アンド イノヴェイション ポリシー カウンシル filed Critical バイオ アドヴェンチャー カンパニー リミテッド
Publication of JP2025509106A publication Critical patent/JP2025509106A/ja
Publication of JP2025509106A5 publication Critical patent/JP2025509106A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024549763A 2022-03-21 2023-03-21 タンパク質発現を増強するための、配列内リボソーム進入部位（ＩＲＥＳ）、プラスミドベクター及び環状ｍＲＮＡ Pending JP2025509106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TH2201001686 2022-03-21
TH2201001686 2022-03-21
PCT/TH2023/000003 WO2023182948A1 (en) 2022-03-21 2023-03-21 Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression

Publications (2)

Publication Number Publication Date
JP2025509106A true JP2025509106A (ja) 2025-04-11
JP2025509106A5 JP2025509106A5 (https=) 2026-04-01

Family

ID=86054332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549763A Pending JP2025509106A (ja) 2022-03-21 2023-03-21 タンパク質発現を増強するための、配列内リボソーム進入部位（ＩＲＥＳ）、プラスミドベクター及び環状ｍＲＮＡ

Country Status (6)

Country Link
US (1) US20250243507A1 (https=)
EP (1) EP4496598A1 (https=)
JP (1) JP2025509106A (https=)
CN (1) CN118871134A (https=)
AU (1) AU2023240827A1 (https=)
WO (1) WO2023182948A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024234874A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026006644A1 (en) * 2024-06-26 2026-01-02 Emervax, Inc. Circular mrna yellow fever vaccine
WO2026006593A1 (en) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Synthetic internal ribosome entry sites
CN119464284B (zh) * 2024-09-29 2026-02-13 复旦大学附属肿瘤医院 一种用于免疫细胞高效蛋白表达的环形rna疫苗平台及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2996697B1 (en) 2013-05-15 2019-06-26 Robert Kruse Intracellular translation of circular rna
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
BR112021023411A2 (pt) 2019-05-22 2022-02-01 Massachusetts Inst Technology Composições e métodos de rna circular
CN114981409A (zh) * 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
AU2021269137A1 (en) * 2020-05-08 2022-12-15 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2021236855A1 (en) * 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
IL298362A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
AU2021300378A1 (en) * 2020-07-01 2023-01-19 Elevatebio Technologies, Inc. Compositions and methods for cellular reprogramming using circular RNA
US20230346921A1 (en) * 2020-08-21 2023-11-02 Peking University Circular rna vaccines and methods of use thereof
AU2021336976A1 (en) * 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
BR112023023642A2 (pt) * 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
CN115404240A (zh) * 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
TW202317767A (zh) * 2021-06-10 2023-05-01 美商歐納醫療公司 環狀rna組合物及方法
CN115702940A (zh) * 2021-08-05 2023-02-17 苏州科锐迈德生物医药科技有限公司 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
EP4496598A1 (en) 2025-01-29
AU2023240827A1 (en) 2024-07-18
US20250243507A1 (en) 2025-07-31
CN118871134A (zh) 2024-10-29
WO2023182948A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US20250243507A1 (en) Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression
US12570996B2 (en) Circular RNA for translation in eukaryotic cells
Zhang et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Pardi et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
WO2008140126A1 (ja) １本鎖環状ｒｎａおよびその製造方法
US20240091343A1 (en) Technology platform of uncapped-linear mrna with unmodified uridine
EP4349990A1 (en) Artificial polynucleotides for expressing proteins
CN117205309B (zh) 一种流感免疫原组合物和制备方法及其用途
CN119855906A (zh) 包含改善mRNA细胞内稳定性和生物合成的UTR序列的构建体及其用途
CN119752906B (zh) 一种5’utr及其应用
CN114807154A (zh) 一种修饰的核酸及其应用
HK40116935A (zh) 用於增强蛋白质表达的内部核糖体进入位点(ires)、质粒载体和环状mrna
Zhang et al. Airway applied IVT mRNA vaccine needs specific sequence design and high standard purification that removes devastating dsRNA contaminant
AU2023201630B2 (en) Circular RNA for translation in eukaryotic cells
KR102918706B1 (ko) mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
US20260125673A1 (en) Artificial polynucleotides for expressing proteins
WO2024198028A1 (zh) 一种重组核酸载体及其在制备环状rna分子中的用途
CN121226501A (zh) 一种自复制元件、自复制rna分子及其用途
HK40077179B (zh) 一种修饰的核酸及其应用
Kumar et al. PCR-generated DNA templates enable efficient, rapid, and cost-effective mRNA synthesis
CN120242020A (zh) Ago2在制备治疗脂肪肝或高脂血症的药物方面的用途及其产品
CN121450760A (zh) 一种快速高通量加帽效率检测方法及其筛选utr序列的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323